Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc?RI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Saved in:
Bibliographic Details
Title: Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc?RI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Authors: Repp, R.1 Roland.Repp@med3.imed.uni-erlangen.de, van Ojik, H.H.2,3, Valerius, T.1, Groenewegen, G.2, Wieland, G.4, Oetzel, C.1, Stockmeyer, B.1, Becker, W.5, Eisenhut, M.6, Steininger, H.7, Deo, Y.M.8, Blijham, G.H.2, Kalden, J.R.1, van de Winkel, J.G.J.3,9, Gramatzki, M.1
Source: British Journal of Cancer. 12/15/2003, Vol. 89 Issue 12, p2234-2243. 10p.
Database: Academic Search Ultimate
Description
ISSN:00070920
DOI:10.1038/sj.bjc.6601367